Carfilzomib 60mg
Product Overview
| Generic Name | Carfilzomib 60mg |
| Brand Name(s) | Biosimilar |
| Category | Antineoplastic / Cancer |
| Form | vial of lyophilized IV powder for solution |
| Strength | 60 mg |
| Therapeutic Class | Antineoplastic, proteasome inhibitor |
| ATC Code | L01XG02 |
Manufacturing & Regulatory
| Manufacturer | Biosimilar |
| GMP Compliance | WHO/EMA |
| COFEPRIS | 010.000.6086.00 |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes—lot-specific Certificate of Analysis |
| SDS-Safety Data Sheet (PDF) | Not Avail. |
| CTD Summary (PDF) | Upon Request |
Special Notes
Carfilzomib in biosimialr form is indicated for the treatment of relapsed or refractory multiple myeloma, typically in combination with other agents such as lenalidomide and dexamethasone, or dexamethasone alone.